Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

RECOVERY-AZI (Horby), 2020
 
NCT04381936
RCTazithromycinstandard of careCOVID 19 hospitalizedsome concern
2582/5182 inconclusive
  • inconclusive 0 % increase in deaths,deaths (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
Preliminary findings based on a data cut on 30 November. Final results will be made available after the last patient has completed the 28-day follow-up period for the primary outcome on 25 December 2020
Sekhavati, 2020 RCTazithromycinlopinavir/ritonavirCOVID 19 hospitalizedsome concern
56/55 inconclusive
  • inconclusive 51 % decrease in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
Sekhavati, 2020 RCTazithromycinhydroxychloroquineCOVID 19 hospitalizedsome concern
56/55 inconclusive
  • inconclusive 51 % decrease in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
Rodriguez-Molinero, 2020 OBSazithromycinCOVID 19 hospitalizedNA
-/- ongoing
    Our study did not find a benefit associated with the use of azithromycin in terms of respiratory function (SAFI)
    Rodriguez-Molinero, 2020 OBSazithromycincontrolCOVID 19 hospitalizedNA
    -/- inconclusive
      Our study did not find a benefit associated with the use of azithromycin in terms of respiratory function (SAFI)
      Rosenberg, 2020 OBSazithromycincontrolCOVID 19 hospitalizedserious
      -/- inconclusive

        COVID-19 mild to moderate meta-analysis

        Espitia-Hernandez, 2020 NRaazithromycinstandard of careCOVID 19 outpatients, COVID-19 mild to moderateNA
        28/7 suggested
        • suggested 714.0-fold increase in PCR-negative conversion

        COVID-19 severe or critically meta-analysis

        COALITION II (Furtado), 2020
         
        NCT04321278
        RCTazithromycinhydroxychloroquineCOVID-19 severe or criticallysome concern
        214/183 inconclusive

          PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
          Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).